A study in healthy people to test how 2 different formulations of BI 690517 are taken up in the body and how probenecid influences the amount of BI 690517 in the blood

2024-513590-45-00 Protocol 1378-0025 Human pharmacology (Phase I) - Other Ended

Start 12 Nov 2024 · End 7 Jan 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1378-0025

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 15
Countries 1
Sites 1

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
12 Nov 2024 → 7 Jan 2025
Decision date (initial)
2024-09-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-513590-45-00
WHO UTN
U1111-1307-2145

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 15 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Boehringer Ingelheim Pharma GmbH & Co. KG
Human Pharmacology Center Biberach / Global Clinical Development & Operations, Birkendorfer Strasse 65, 88397, Biberach An Der Riss

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-11-12 2025-01-07 2024-11-13 2024-11-26

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-30 Germany Acceptable
2024-09-02
2024-09-11